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1,25(OH)2D3 but not SXR ligands induce CYP24 gene expression in 

































Expression of SXR/PXR, VDR, and their target genes in various tis-
sues. (A) Total RNA was isolated from human liver, intestine, and kid-
ney tissues (n = 3), and the expression of SXR, VDR, CYP3A4, and 
CYP24 was analyzed by QRT-PCR. (B) Total RNA was isolated from 
mouse liver, intestine, and kidney tissues (n = 3), and the expression of 
PXR, VDR, CYP3A11, and CYP24 was analyzed by QRT-PCR.
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1,25(OH)2D3 but not SXR ligands induce CYP24 
gene expression in human primary hepatocytes 
and intestinal cells. (A and B) Human primary 
hepatocytes from 2 different donors were treated 
with 1, 10, or 50 nM of the VDR ligand 1,25(OH)2D3 
or 10 mM of SXR ligands RIF, CLOT, or RU486 for 
24 hours as indicated. Total RNA from each sam-
ple was isolated, and the expression of CYP3A4 
and CYP24 genes was determined by QRT-PCR 
assays. (C) Two different immortalized human intes-
tinal cell lines, Caco-2 and LS180, were treated with 
1, 10, or 100 nM of the VDR ligand 1,25(OH)2D3 or 
10 mM of SXR ligands RIF, CLOT, or RU486 for 
24 hours as indicated. Total RNA from each sam-
ple was isolated, and the expression of CYP3A4 
and CYP24 genes was determined by QRT-PCR 
assays. (D) Human primary hepatocytes from 
donor 3 were treated with 10 or 50 nM of the VDR 
ligand 1,25(OH)2D3 or 10 mM of SXR ligands RIF, 
CLOT, or RU486 for 24, 48, or 72 hours as indicat-
ed. Total RNA from each sample was isolated, and 
the expression of CYP24 genes was determined by 
QRT-PCR assays. (E) LS180 cells were transfected 
with control vector, VP16, or VP16-SXR expression 
vector; total RNA from each sample was isolated; 
and the expression of CYP3A4 and CYP24 genes 
was determined by QRT-PCR assays.
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VDR but not SXR transactivates the CYP24 promoter. (A) HepG2 
cells were transiently transfected with full-length VDR together with a 
CYP3A4-luc reporter or CYP24-luc reporter and CMX-β-galactosidase 
transfection control plasmid. After transfection, cells were treated with 
control medium or medium containing 1 or 10 nM 1,25(OH)2D3 for 24 
hours. (B) HepG2 cells were transiently transfected with full-length 
SXR together with a CYP3A4-luc reporter or CYP24-luc reporter and 
CMX–β-galactosidase transfection control plasmid. After transfection, 
cells were treated with control medium or medium containing 10 mM 
CLOT, RIF, or RU486 for 24 hours.
Figure 4
SXR does not bind to the VDRE-1 and VDRE-2 motifs in the CYP24 promoter region. (A) In vitro–translated VDR, SXR, and RXR, as indicated, 
were incubated with [32P]-labeled VDRE-1 or VDRE-2 probe and analyzed by EMSA. Ten- or 50-fold excess of unlabeled VDRE-1 or VDRE-2 
probes was used for competition experiments. (B) In vitro–translated SXR and RXR were incubated with a [32P]-labeled ER6 motif, and 10- or 
50-fold excess of unlabeled ER6, VDRE-1, or VDRE-2 probes was used for competition experiments. (C and D) In vitro–translated VDR and RXR 
were incubated with [32P]-labeled VDRE-1 (C) or VDRE-2 (D) along with increasing amounts of SXR or RXR protein and analyzed by EMSA.
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Treatment with the SXR agonist RIF induces duodenal CYP3A4 but 



















Crosstalk between SXR and VDR coordinately regu-


















Induction of duodenal CYP3A4 but not CYP24 expression in healthy 
volunteers treated with RIF. The duodenal epithelial biopsy samples 
were collected from 6 healthy human volunteers before and after 2, 7, 
or 14 days of oral RIF administration (150 mg every 6 hours). Total RNA 
was isolated from biopsy samples, and the expression of CYP3A4 and 
CYP24 was analyzed by QRT-PCR. ND, not detectable. Statistically 
significant expressions compared with conditions before RIF adminis-
tration (day 0) are marked with asterisks; *P < 0.05 and **P < 0.01.
Figure 6
Crosstalk between SXR and VDR coordinately 
regulates CYP24 promoter activity. HepG2 cells 
were transiently transfected with SXR or/and VDR 
expression plasmids along with a CYP24-luc report-
er and CMX–β-galactosidase control plasmid, as 
indicated. (A) After transfection, cells were treated 
with control medium or medium containing 1, 10, or 
100 nM 1,25(OH)2D3 and 10 mM RIF as indicated for 
24 hours. (B) After transfection, cells were treated 
with 100 nM 1,25(OH)2D3 and 1, 5, and 10 mM RIF 
for 24 hours. (C) HepG2 cells were transfected with 
increasing amounts of SXR at 1:1, 2:1, or 4:1 ratio 
with VDR expression vector. After transfection, cells 
were treated with 100 nM 1,25(OH)2D3.
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SXR inhibits VDR effects on osteopontin and osteocalcin promoter 




























promoter  activity  (Figure  7C).  These  data  suggest  that  SXR 
represses VDR activation of some target genes, such as CYP24, OC, 
and SPP, but not the common target gene, CYP3A4.
Pregnenolone 16a-carbonitrile does not induce CYP24 expression in 





SXR inhibits VDR effects on SPP and OC promoter activities but 
not on their common target gene, CYP3A4. HepG2 cells were 
transfected with SXR and VDR expression plasmids along with 
an SPP2-luc reporter (A), OC-luc reporter (B), or CYP3A4-luc 
(C) reporter and CMX–β-galactosidase control plasmid, as indi-
cated. After transfection, cells were treated with control medium 
or medium containing 1 or 10 nM 1,25(OH)2D3 and 10 mM RIF, as 
indicated, for 24 hours.
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Activation of mouse PXR by PCN does not induce CYP24 expres-
sion in mice, and VDR-mediated CYP24 expression is enhanced by 
PXR knockout. Ten-week-old male PXR-knockout and C57BL6/J 
(wild-type) mice (3 per group) were injected intraperitoneally with 
vehicle control (DMSO), PXR ligand PCN (40 mg/kg), or VDR 
ligand 1,25(OH)2D3 (50 ng/mouse) for 3 consecutive days. Tissues 
were collected, and gene expression in the specific tissues was 
determined by QRT-PCR. (A) Expression of the PXR target gene 
CYP3A4 in PXR-knockout or WT mice was determined by QRT-
PCR. Total RNA was isolated from liver and intestine, as indicated. 
(B) Expression of the VDR target gene CYP24 in PXR-knockout or 
WT mice was determined by QRT-PCR. Total RNA was isolated 
from liver, intestine, and kidney, as indicated. *P < 0.05, **P < 0.01, 
and #P < 0.001.
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Aldrich.  1,25(OH)2D3 was  purchased  from  Calbiochem,  and  PCN  was 
purchased from BioMol International. SXR, VDR, VP16-SXR, CMX–β-gal 
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GACAAAAGGC-3′  and  5′-CTAACCGTCGGTCATCAGC-3′);  mouse 
VDR  (5′-ACCCTGGTGACTTTGACCG-3′  and  5′-GGCAATCTCCATT-
GAAGGGG-3′);  mouse  PXR  (5′-GACGCTCAGATCCAAACCTT-3′  and 
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